820224-51-9 Usage
Uses
Used in Pharmaceutical Industry:
2,6-DICHLORO-5-FLUORO-3-(HYDROXYMETHYL)PYRIDINE is used as a chemical intermediate for the synthesis of various drugs and pharmaceuticals. Its unique structure allows for the development of new chemical entities with potential therapeutic benefits.
Used in Research and Development:
In the field of research and development, 2,6-DICHLORO-5-FLUORO-3-(HYDROXYMETHYL)PYRIDINE serves as a key building block for the production of novel chemical compounds. Its properties enable scientists to explore its potential in creating new drugs and other chemical entities.
Used in Agrochemical and Pesticide Synthesis:
2,6-DICHLORO-5-FLUORO-3-(HYDROXYMETHYL)PYRIDINE is also utilized as a building block in the synthesis of agrochemicals and pesticides. Its chemical structure contributes to the development of effective and targeted pest control solutions.
Safety Precautions:
Despite its potential applications, 2,6-Dichloro-5-fluoro-3-(hydroxymethyl)pyridine should be handled with care due to its potential hazards to human health and the environment. Proper safety measures and disposal methods should be followed to minimize any adverse effects.
Check Digit Verification of cas no
The CAS Registry Mumber 820224-51-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,2,0,2,2 and 4 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 820224-51:
(8*8)+(7*2)+(6*0)+(5*2)+(4*2)+(3*4)+(2*5)+(1*1)=119
119 % 10 = 9
So 820224-51-9 is a valid CAS Registry Number.
820224-51-9Relevant articles and documents
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
-
Page/Page column 84, (2010/12/29)
The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3
-
Page/Page column 20, (2008/06/13)
Fused heterotricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.
